

Product datasheet for **TR306698**

ANKRD17 Human shRNA Plasmid Kit (Locus ID 26057)

Product data:

Product Type:	shRNA Plasmids
Product Name:	ANKRD17 Human shRNA Plasmid Kit (Locus ID 26057)
Locus ID:	26057
Synonyms:	GTAR; MASK2; NY-BR-16
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	ANKRD17 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 26057). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	BC004173 , NM_001286771 , NM_015574 , NM_032217 , NM_198889 , NM_198889.1 , NM_198889.2 , NM_032217.1 , NM_032217.2 , NM_032217.3 , NM_032217.4 , NM_001286771.1 , NM_001286771.2 , BC004891 , BC007747 , BC009043 , BC019963 , BC029935 , BC043394 , BC146382 , BM755557 , BM971664
UniProt ID:	O75179
Summary:	The protein encoded by this gene belongs to the family of ankyrin repeat-containing proteins, and contains two distinct arrays of ankyrin repeats in its amino-terminal region, one with 15 ankyrin repeats, and the other with 10 ankyrin repeats. It also contains a nuclear export signal, nuclear localization signal, and a cyclin-binding RXL motif. Localization of this protein to the nucleus has been shown experimentally, and interactions between this protein and cyclin-dependent kinase 2 have been observed. It has been suggested that this protein plays a role in both DNA replication and in both anti-viral and anti-bacterial innate immune pathways. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Dec 2015]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).